Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs

Journal of the National Cancer Institute

Volumn 96, Issue 22, 2004, Pages 1702-1713

  Luciani, Francesca ^a   Spada, Massimo ^a   De Milito, Angelo ^a   Molinari, Agnese ^a   Rivoltini, Licia ^b   Montinaro, Annalisa ^a   Marra, Manuela ^a   Lugini, Luana ^a   Logozzi, Mariantonia ^a   Lozupone, Francesco ^a   Federici, Cristina ^a   Iessi, Elisabetta ^a   Parmiani, Giorgio ^b   Arancia, Giuseppe ^a   Belardelli, Filippo ^a   Fais, Stefano ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; ESOMEPRAZOLE; FLUOROURACIL; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; VINBLASTINE;

ACIDIFICATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CARCINOMA CELL; CELL CYCLE; CELL DEATH; CELL PH; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; HAIR DISEASE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; LASER MICROSCOPY; LYMPHOMA CELL LINE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SOLID TUMOR; WEIGHT REDUCTION; WESTERN BLOTTING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BLOTTING, WESTERN; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLUOROURACIL; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; LYMPHOMA; MELANOMA; MICE; MICE, SCID; MICROSCOPY, CONFOCAL; OMEPRAZOLE; PROTON PUMPS; SULFOXIDES; TRANSPLANTATION, HETEROLOGOUS; VINBLASTINE;

EID: 9744260934     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh305     Document Type: Article

References (53)

1. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
2. Mahoney BP, Raghunand N, Bagget B, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 2003;66:1207-18.
3. Simon S, Roy D, Schindler M. Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci U S A 1994;91:1128-32.
4. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989;49:4373-84.
5. Izumi H, Torigoe T, Ishiguchu H, Uramoto H, Yoshida Y, Tanabe M, et al. Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev 2003;29:541-9.
6. Raghunand N, He X, van Sluis R, Mahoney BP, Bagget B, Tayloe CW, et al. Enhancement of chemotherapy by manipulation of tumor pH. Br J Cancer 1999;80:1005-11.
7. Raghunand N, Martinez-Zaguilan R, Wright SH, Gillies RJ. pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem Pharmacol 1999;57:1047-58.
8. Raghunand N, Mahoney BP, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic therapeutic agents. Biochem Pharmacol 2003;66:1219-29.
9. Altan N, Chen Y, Schindler M, Sanford SM. Defective acidification in human breast tumor cells and implications for chemotherapy. J Exp Med 1998;187:1583-98.
10. Hurwitz SJ, Terashima M, Mizunuma N, Slapak CA. Vesicular anthracycline accumulation in doxorubicin-selected U937 cells: participation of lysosomes. Blood 1997;89:3745-54.
11. Schindler M, Grabski S, Hoff E, Simon SM. Defective pH regulation of acidic compartments in human breast cancer cells (MCF-7) is normalized in adriamycin-resistant cells (MCF-7adr). Biochemistry 1996;35:2811-7.
12. Larsen AK, Escargueil AE, Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 2000;85:217-29.
13. Bour-Dill C, Gramain MP, Merlin JL, Marchal S, Guillemin F. Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis. Cytometry 2000;39:16-25.
14. Cleary I, Doherty G, Moran E, Clynes M. The multidrug-resistant human lung tumour cell line, DLKP-A10, expresses novel drug accumulation and sequestration systems. Biochem Pharmacol 1997;53:1493-502.
15. Bobichon H, Colin M, Depierreux C, Liautaud-Roger F, Jardillier JC. Ultrastructural changes related to multidrug resistance in CEM cells: role of cytoplasmic vesicles in drug exclusion. J Exp Ther Oncol 1996;1:49-61.
16. Dietel M, Arps H, Lage H, Niendorf A. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res 1990;50:6100-6.
17. Ouar Z, Lacave R, Bens M, Vandewalle A. Mechanisms of altered sequestration and efflux of chemotherapeutic drugs by multidrug resistant cells. Cell Biol Toxicol 1999;15:91-100.
18. Ouar Z, Bens M, Vignes C, Paulais M, Pringel C, Fleury J, et al. Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells. Biochem J 2003;370:185-93.
19. Nishi T, Forgac M. The vacuolar (H+)-ATPases - nature's most versatile proton pumps. Nat Rev Mol Cell Biol 2002;3:94-103.
20. Beck WT. The cell biology of multiple drug resistance. Biochem Pharmacol 1987;36:2879-87.
21. Vaananen HK, Karhukorpi EK, Sunquist K, Wallmark B, Roinine I, Hentune T, et al. Evidence of the presence of H+-ATPase types in the ruffled borders of osteoclasts. J Cell Biol 1990;111:1305-11.
22. Marquardt D, Center MS. Involvement of vacuolar H+-adenosine triphosphatase activity in multidrug resistance in HL60 cells. J Natl Cancer Inst 1991;83:1098-1102.
23. Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ. Vacuolar-type H(+)-ATPases are functionally expressed in the plasma membranes of human tumor cells. Am J Physiol 1993;265(4 Pt 1):C1015-29.
24. Moriyama Y. Membrane energization by proton pumps is important for compartmentalization of drugs and toxins: a new type of active transport. J Exp Biol 1996;199:1447-54.
25. Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama S, Nakagawa M, et al. Elevated expression of vacuolar proton pump genes and cellular pH in cisplatin resistance. Int J Cancer 2001;93:869-74.
26. Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000;22:266-80.
27. Wallmark B, Larsson H, Humble L. The relationship between gastric acid sectetion and gastric H+, K+-ATPase activity. J Biol Chem 1985;260:13681-4.
28. Wallmark B, Lorentzon P, Larsson H. The mechanism of action of omeprazole - a survey of its inhibitory action in vitro. Scand J Gastroenterol Suppl 1985;108:37-51.
29. Puscas I, Coltau M, Baican M, Domuta G. Omeprazole has a dual mechanism of action: it inhibits both H(+)K(+)ATPase and gastric mucosa carbonic anhydrase enzyme in humans (in vitro and in vivo experiments). J Pharmacol Exp Ther 1999;290:530-4.
30. Larsson H, Mattson H, Sundell G, Carlsson E. Animal pharmacodynamics of omeprazole. A survey of its pharmacological properties in vivo. Scand J Gastroenterol Suppl 1985;108:23-35.
31. Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993;53:21-5.
32. Graber ML, Devine P. Omeprazole and SCH 28080 inhibit acid secretion by the turtle urinary bladder. Ren Physiol Biochem 1993;16:257-67.
33. Sabolic I, Brown D, Verbavatz JM, Kleinman J. H(+)-ATPases of renal cortical and medullary endosomes are differentially sensitive to Sch-28080 and omeprazole. Am J Physiol 1994;266(6 Pt 2):F868-77.
34. Cianfriglia M, Cenciarelli C, Tombesi M, Barca S, Mariani M, Morroni S, et al. Murine monoclonal antibody recognizing a 90-kDa cell-surface determinant selectively lost by multi-drug-resistant variants of CEM cells. Int J Cancer 1990;45:95-103.
35. Luciani F, Matarrese P, Giammarioli AM, Lugini L, Lozupone F, Federici C, et al. CD95/phosphorylated ezrin association underlies HIV-1 GP120/IL-2-induced susceptibility to CD95 (APO-1/Fas)-mediated apoptosis of human resting CD4(+)T lymphoctes. Cell Death Differ 2004;11:574-82.
36. Luciani F, Molinari A, Lozupone F, Calcabrini A, Lugini L, Stringaro A, et al. P-glycoprotein/actin association through ERM family proteins: a role in P-glycoprotein function in human cells of lymphoid origin. Blood 2002;99:641-8.
37. Garewal HS, Ahmann FR, Schifman RB, Celniker A. ATP assay: ability to distinguish cytostatic from cytocidal anticancer drug effects. J Natl Cancer Inst 1986;77:1039-45.
38. Lugini L, Lozupone F, Matarrese P, Funaro C, Luciani F, Malorni W, et al. Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin. Lab Investig 2003;83:1555-67.
39. Bosma MJ, Carroll AM. The SCID mouse mutant: definition, characterization, and potential uses. Annu Rev Immunol 1991;9:323-50.
40. Watson SA, Smith AM. Hypergastrinaemia promotes adenomaprogression in the APCMin7/+ mouse model of familial adenomatous polyposis. Cancer Res 2001;61:625-31.
41. Son K, Huang L. Exposure of human ovarian carcinoma to cisplatin transiently sensitizes the tumor cells for liposome-mediated gene transfer. Proc Natl Acad Sci U S A 1994;91:12669-72.
42. Geran RI, Greenberg NH, Macdonald MM, Shumacher AM, Abbot BJ. Protocols for screening chemical agents and natural products against animal tumors and natural other biological systems. Cancer Chemother Rep 1972;3:1-88.
43. Lozupone F, Luciani F, Venditti M, Rivoltini L, Pupa S, Parmiani G, et al. Murine granulocytes control human tumor growth in SCID mice. Int J Cancer 2000;87:569-73.
44. Lozupone F, Rivoltini L, Luciani F, Venditti M, Lugini L, Cova A, et al. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. Eur J Immunol 2003;33:556-66.
45. Lozupone F, Pende D, Burgio VL, Castelli C, Spada M, Venditti M, et al. Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice. Cancer Res 2004;64:378-85.
46. Martinez-Zaguilan R, Raghunand N, Lynch RM, Bellamy W, Martinez GM, Rojas B, et al. pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol 1999;57:1037-46.
47. Sennoune SR, Bakunts K, Martinez GM, Chua-Tuan JL, Kebir Y, Attaya MN, et al. Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol 2004;286:C1443-52.
48. Torigoe T, Izumi H, Murakami T, Uramoto H, Ishiguchi H, Yoshida Y, et al. Vacuolar H(+)-ATPase: functional mechanisms and potential as a target for cancer chemotherapy. Anticancer Drugs 2002;13:237-43.
49. Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002;195:1303-16.
50. Vitavska O, Wieczorek H, Merzendorfer H. A novel role for subunit C in mediating binding of the H+-V-ATPase to the actin cytoskeleton. J Biol Chem 2003;278:18499-505.
51. Zhou R, Cao X, Watson C, Miao Y, Guo Z, Forte JG, et al. Characterization of protein kinase A-mediated phosphorylation of ezrin in gastric parietal cell activation. J Biol Chem 2003;278:35651-9.
52. Chasan B, Geisse NA, Pedatella K, Wooster DG, Teintze M, Carattino MD, et al. Evidence for direct interaction between actin and the cystic fibrosis transmembrane conductance regulator. Eur Biophys J 2002;30:617-24.
53. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.